Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK

被引：0
|
作者：
Mughal, F. [1 ]
Barker, J. [2 ]
Cawston, H. [3 ]
Damera, V. [3 ]
Bewley, A. [4 ,5 ]
Morris, J. [6 ]
Shaw, T. [7 ]
Tencer, T. [8 ]
Zhang, F. [8 ]
机构：
[1] Celgene Ltd, Uxbridge, Middx, England
[2] St Johns Inst Dermatol Kings Coll, London, England
[3] Mapi Grp, London, England
[4] Whipps Cross Univ Hosp, London, England
[5] Royal London Hosp, London, England
[6] Cogentia Healthcare Consulting, Cambridge, England
[7] Celgene Ltd, Southall, Middx, England
[8] Celgene Corp, Summit, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2016年 / 175卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P108
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [2] Cost-effectiveness of apremilast in moderate to severe psoriasis in the UK
    Mughal, Farhan
    Barker, Jonathan
    Cawston, Helene
    Damera, Vidya
    Bewley, Anthony
    Morris, James
    Shaw, Tim
    Tencer, Tom
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB243 - AB243
  • [3] Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
    Gisondi, Paolo
    Girolomoni, Giampiero
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1763 - 1770
  • [4] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Christou, P.
    Relakis, J.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S74 - S74
  • [5] COST-EFFECTIVENESS OF APREMILAST IN MODERATE TO SEVERE PSORIASIS IN SCOTLAND
    Mughal, F.
    Cawston, H.
    Kinahan, D.
    Morris, J.
    Tencer, T.
    Zhang, F.
    VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [6] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
    Valencia-Mendoza, A.
    Hernandez-Garduno, A.
    Puig, A.
    VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
  • [7] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [8] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [9] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
  • [10] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
12345